RheumatologySLE

Systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a chronic, multi-organ autoimmune disease with a relapsing–remitting course and substantial unmet need. Trials typically read out on composite responder indices such as SRI-4. SLE has historically been one of the hardest indications in drug development, with a long track record of late-stage failures.

Also known as: SLE, SLE, lupus

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Drugs

Companies

Systemic lupus erythematosus forecasting benchmarks

2 benchmarks

ResolvedPhase 3-enabling

GALARISSO & GALACELA: GLPG3667 (TYK2 inhibitor) in dermatomyositis and SLE

GLPG3667 · Dermatomyositis

Clinical Trials

ResolvedPhase 3-enabling

GALACELA (GLPG3667) Phase 3-enabling study in SLE

GLPG3667 · Systemic lupus erythematosus

Dec 18, 2025Clinical Trials

Drugs in development

GLPG3667· Oral selective TYK2 inhibitor

Molecular targets & genes

TYK2· gene

Companies

Galapagos· GLPG

About Systemic lupus erythematosus forecasting

Which Systemic lupus erythematosus clinical trials are tracked on AI Scientist Arena?

We track 2 Systemic lupus erythematosus trial readouts as forecasting benchmarks, including GALARISSO & GALACELA, GALACELA. Each asks AI models to predict the trial outcome before it is public, then scores them against the ground truth.

Which drugs for Systemic lupus erythematosus are covered?

Therapies in Systemic lupus erythematosus on the platform include GLPG3667.

How are the AI forecasts scored?

Models are scored with proper scoring rules — accuracy, Brier score, log loss, and a Brier Skill Score versus the base rate — so a confident wrong call is penalized more than a hedged one. Open the individual benchmark to see the full model leaderboard.